Research Papers:
Circulating microparticles are prognostic biomarkers in advanced non-small cell lung cancer patients
Metrics: PDF 2475 views | HTML 2866 views | ?
Abstract
Chin-Chou Wang1,2,3,*, Chia-Cheng Tseng1,4,*, Huang-Chih Chang1,4, Kuo-Tung Huang1,4, Wen-Feng Fang1,3, Yu-Mu Chen1, Cheng-Ta Yang5, Chang-Chun Hsiao4,6,**, Meng-Chih Lin1,**, Chi-Kung Ho2,** and Hon-Kan Yip6,7,8,9,10,**
1Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine, Kaohsiung Chang Gung Memorial Hospital, Chang Gung University College of Medicine, Kaohsiung, Taiwan
2Department of Public Health, Kaohsiung Medical University, Kaohsiung, Taiwan
3Department of Respiratory Care, Chang Gung University of Science and Technology, Chiayi Campus, Chiayi, Taiwan
4Graduate Institute of Clinical Medical Sciences, Chang Gung University College of Medicine, Kaohsiung, Taiwan
5Department of Pulmonary and Critical Care Medicine, Chang Gung Memorial Hospital, Chang Gung University College of Medicine, Taoyuan, Taiwan
6Center for Shockwave Medicine and Tissue Engineering, Kaohsiung Chang Gung Memorial Hospital and Chang Gung University College of Medicine, Kaohsiung, Taiwan
7Division of cardiology, Department of Internal Medicine, Kaohsiung Chang Gung Memorial Hospital and Chang Gung University College of Medicine, Kaohsiung, Taiwan
8Department of Medical Research, China Medical University Hospital, China Medical University, Taichung, Taiwan
9Department of Nursing, Asia University, Taichung, Taiwan
10Institute for Translational Research in Biomedicine, Kaohsiung Chang Gung Memorial Hospital, Kaohsiung, Taiwan
*These authors contributed equally to this work and should be considered co-first authors
**These authors contributed equally to this work and should be considered co-correspondence authors
Correspondence to:
Hon-Kan Yip, email: [email protected]
Keywords: advanced non-small cell lung cancer, microparticles, disease control, disease progression
Received: January 09, 2017 Accepted: April 25, 2017 Published: June 06, 2017
ABSTRACT
We investigated whether circulating microparticles (MPs) could serve as prognostic biomarkers in non-small cell lung cancer (NSCLC) patients. We enrolled 25 control subjects and 136 NSCLC patients categorized into disease-progression (DP, n=42) and disease-control (DC, n=94) groups. Flow cytometric analysis showed that levels of four types of circulating microparticles (EDAc-MPs, EDAp-MPs, PDAc-MPs and PDAp-MPs) were higher in the study patients than the control subjects (P < 0.04). DP patients showed poor initially performance status and more non-adenocarcinomas than DC patients. DC patients showed more EGFR mutations and poorer performance to targeted therapy than DP patients (P < 0.01). Three months after therapy, the levels of all four types of circulating MPs were lower in DC than DP patients (P < 0.02), and were comparable to the levels in control subjects. In addition, the levels of circulating MPs after 3 months accurately predicted one-year prognostic outcomes (P < 0.05). This study showed that circulating MPs are valuable prognostic biomarkers in advanced NSCLC patients.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 18372